Progress of biomarkers in liver cancer

doi:10.3760/cma.j.cn371439-20200409-00048

Abstract

Abstract:

With the development of detection methods, various biomarkers of liver cancer have been detected constantly, which is of great significance for the early diagnosis and real-time monitoring of liver cancer after treatment. Based on the differences in the sensitivity and specificity of different biomarkers, exploration of the value of diverse biomarkers in the diagnosis and prognosis assessment of liver cancer can provide an important reference for clinicians to scientific and rational application of distinct biomarkers.

Key words: Liver neoplasms, Biomarkers, Early diagnosis

Zhang Yuyuan, Li Zhen, Zhan Pengchao, Li Xin, Ye Shuwen, Wang Caihong, Liu Yang. Progress of biomarkers in liver cancer[J]. Journal of International Oncology, 2021, 48(4): 241-245.

References 45

[1]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. DOI: 10.3322/caac.21338. doi: 10.3322/caac.21338
[2]	Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1):358-380. DOI: 10.1002/hep.29086. doi: 10.1002/hep.29086 pmid: 28130846
[3]	梁锋, 施宝民. 当今肝癌诊治中经典标志物AFP研究新进展[J]. 中华肝胆外科杂志, 2009, 15(4):316-320. DOI: 10.3760/cma.j.issn.1007-8118.2009.04.026.
[4]	Park SJ, Jang JY, Jeong SW, et al. Usefulness of AFP, AFP-L3, and PIVKA-Ⅱ, and their combinations in diagnosing hepatocellular carcinoma[J]. Medicine (Baltimore), 2017, 96(11): e5811. DOI: 10.1097/MD.0000000000005811. doi: 10.1097/MD.0000000000005811
[5]	Cheng J, Wang W, Zhang Y, et al. Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis[J]. PLoS One, 2014, 9(1): e87011. DOI: 10.1371/journal.pone.0087011. doi: 10.1371/journal.pone.0087011
[6]	杨沛, 贾喻惠, 蔡晓娜, 等. 血清α-L-岩藻糖苷酶对原发性肝癌的诊断价值[J]. 国际检验医学杂志, 2016, 37(24):3467-3468. DOI: 10.3969/j.issn.1673-4130.2016.24.032.
[7]	刘纯岳, 林帝金, 方俊粤, 等. 健康成年人血清α-L-岩藻糖苷酶参考区间的建立及适用性评价[J]. 现代检验医学杂志, 2018, 33(5):102-104, 107.DOI: 10.3969/j.issn.1671-7414.2018.05.027.
[8]	Junna Z, Gongde C, Jinying X, et al. Serum AFU, 5'-NT and AFP as biomarkers for primary hepatocellular carcinoma diagnosis[J]. Open Med (Wars), 2017, 12:354-358. DOI: 10.1515/med-2017-0051.
[9]	Abouzied MM, Eltahir HM, Fawzy MA, et al. Estimation of leucine aminopeptidase and 5-nucleotidase increases alpha-fetoprotein sensitivity in human hepatocellular carcinoma cases[J]. Asian Pac J Cancer Prev, 2015, 16(3):959-963. DOI: 10.7314/apjcp.2015.16.3.959. doi: 10.7314/APJCP.2015.16.3.959
[10]	岳文莉, 田同德, 田同良, 等. CD73在肿瘤免疫微环境中的研究进展[J]. 肿瘤研究与临床, 2019, 31(1):62-65. DOI: 10.3760/cma.j.issn.1006-9801.2019.01.015.
[11]	刘慧敏, 刘平. 采用ROC曲线评价a-L-岩藻糖苷酶,5-核苷酸酶,甲胎蛋白在肝癌诊断、预后预测中的价值[J]. 临床荟萃, 2016, 31(4):414-417. DOI: 10.3969/j.issn.1004-583X.2016.04.017.
[12]	Cao Z, Li Z, Wang H, et al. Algorithm of Golgi protein 73 and liver stiffness accurately diagnoses significant fibrosis in chronic HBV infection[J]. Liver Int, 2017, 37(11):1612-1621. DOI: 10.1111/liv.13536. doi: 10.1111/liv.2017.37.issue-11
[13]	张克钊. 血清GP73、AFP、Fer、CA199四种肿瘤标志物联合检测对原发性肝癌诊断价值探讨[J]. 实验与检验医学, 2015, 33(6):776-777. DOI: 10.3969/j.issn.1674-1129.2015.06.032.
[14]	吉文伟, 郭胜利, 宋展. 原发性肝癌患者血清GP73的表达及意义[J]. 实验与检验医学, 2018, 36(4):573-575. DOI: 10.3969/j.issn.1674-1129.2018.04.036.
[15]	杨贵敏, 赵运胜, 王春华, 等. 肝细胞癌肿瘤标志物的研究进展[J]. 临床肝胆病杂志, 2018, 34(1):199-203. DOI: 10.3969/j.issn.1001-5256.2018.01.044.
[16]	王秀, 管世鹤, 陈礼文, 等. PIVKA-Ⅱ在原发性肝癌及肝癌合并门静脉癌栓中的诊断价值[J]. 安徽医科大学学报, 2019, 54(9):1471-1475. DOI: 10.19405/j.cnki.issn1000-1492.2019.09.029.
[17]	孙玉, 张洪海, 袁春旺, 等. 肝细胞癌患者微波消融治疗前后血清异常凝血酶原水平变化及临床意义[J]. 临床肝胆病杂志, 2019, 35(3):542-546. DOI: 10.3969/j.issn.1001-5256.2019.03.018.
[18]	熊复, 周锦, 徐樨巍. 低血清γ-谷氨酰转肽酶胆汁淤积性肝病研究进展[J]. 中华实用儿科临床杂志, 2019, 34(22):1754-1757. DOI: 10.3760/cma.j.issn.2095-428X.2019.22.020.
[19]	Hou SC, Xiao MB, Ni RZ, et al. Serum GP73 is complementary to AFP and GGT Ⅱ for the diagnosis of hepatocellular carcinoma[J]. Oncol Lett, 2013, 6(4):1152-1158. DOI: 10.3892/ol.2013.1522. doi: 10.3892/ol.2013.1522
[20]	Song P, Inagaki Y, Wang Z, et al. High levels of gamma-glutamyl transferase and indocyanine green retention rate at 15 min as preoperative predictors of tumor recurrence in patients with hepatocellular carcinoma[J]. Medicine (Baltimore), 2015, 94(21): e810. DOI: 10.1097/MD.0000000000000810. doi: 10.1097/MD.0000000000000810
[21]	Maeda T, Kanzaki H, Chiba T, et al. Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma[J]. BMC Cancer, 2019, 19(1): 1088. DOI: 10.1186/s12885-019-6322-9. doi: 10.1186/s12885-019-6322-9
[22]	Uriarte I, Latasa MU, Carotti S, et al. Ileal FGF 15 contributes to fibrosis-associated hepatocellular carcinoma development[J]. Int J Cancer, 2015, 136(10):2469-2475. DOI: 10.1002/ijc.29287. doi: 10.1002/ijc.29287 pmid: 25346390
[23]	Seitz T, Freese K, Dietrich P, et al. Fibroblast growth factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma[J]. Sci Rep, 2020, 10(1): 4546. DOI: 10.1038/s41598-020-61510-4.
[24]	Iyer MK, Niknafs YS, Malik R, et al. The landscape of long noncoding RNAs in the human transcriptome[J]. Nat Genet, 2015, 47(3):199-208. DOI: 10.1038/ng.3192. doi: 10.1038/ng.3192
[25]	Braconi C, Kogure T, Valeri N, et al. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer[J]. Oncogene, 2011, 30(47):4750-4756. DOI: 10.1038/onc.2011.193. doi: 10.1038/onc.2011.193 pmid: 21625215
[26]	李蒋鹏, 李敬东. 长链非编码RNA对肝细胞肝癌的诊断价值[J]. 中国普外基础与临床杂志, 2019, 26(10):1243-1247. DOI: 10.7507/1007-9424.201903073.
[27]	Zheng ZK, Pang C, Yang Y, et al. Serum long noncoding RNA urothelial carcinoma-associated 1: a novel biomarker for diagnosis and prognosis of hepatocellular carcinoma[J]. J Int Med Res, 2018, 46(1):348-356. DOI: 10.1177/0300060517726441. doi: 10.1177/0300060517726441
[28]	熊伟民, 李明峰, 宋佳鸿, 等. 长链非编码RNA H19促进肝癌细胞增殖和侵袭[J]. 现代生物医学进展, 2013, 13(10):1945-1948. DOI: 10.13241/j.cnki.pmb.2013.10.046.
[29]	胡超, 王新保. microRNA对肝癌细胞生物学行为影响的研究进展[J]. 腹部外科, 2019, 32(5):385-390. DOI: 10.3969/j.issn.1003-5591.2019.05.015.
[30]	Mizuguchi Y, Takizawa T, Yoshida H, et al. Dysregulated miRNA in progression of hepatocellular carcinoma: a systematic review[J]. Hepatol Res, 2016, 46(5):391-406. DOI: 10.1111/hepr.12606. doi: 10.1111/hepr.12606 pmid: 26490438
[31]	Lin XJ, Chong Y, Guo ZW, et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study[J]. Lancet Oncol, 2015, 16(7):804-815. DOI: 10.1016/S1470-2045(15)00048-0. doi: 10.1016/S1470-2045(15)00048-0
[32]	Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs[J]. Nat Biotechnol, 2014, 32(5):453-461. DOI: 10.1038/nbt.2890. doi: 10.1038/nbt.2890
[33]	蒋镇洛, 沈丽丽, 胡耀仁, 等. 环状RNA在原发性肝癌发生中的作用及其潜在价值[J]. 中华肝脏病杂志, 2019, 27(2):157-160. DOI: 10.3760/cma.j.issn.1007-3418.2019.02.018.
[34]	李祎, 王峰, 鞠少卿. 环状RNA在肝细胞肝癌中的研究进展[J]. 肿瘤预防与治疗, 2019, 32(4):361-365. DOI: 10.3969/j.issn.1674-0904.2019.04.013.
[35]	Sun YF, Xu Y, Yang XR, et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection[J]. Hepatology, 2013, 57(4):1458-1468. DOI: 10.1002/hep.26151. doi: 10.1002/hep.26151
[36]	肖晗, 余宏铸. 循环肿瘤细胞在原发性肝细胞肝癌患者中预后预测价值的meta分析[J]. 肝胆外科杂志, 2017, 25(2):98-103.
[37]	Wu C, Li P, Fan N, et al. A dual-targeting functionalized graphene film for rapid and highly sensitive fluorescence imaging detection of hepatocellular carcinoma circulating tumor cells[J]. ACS Appl Mater Interfaces, 2019, 11(48):44999-45006. DOI: 10.1021/acsami.9b18410. doi: 10.1021/acsami.9b18410
[38]	李臻, 石冰涛, 张恒辉, 等. 肝细胞癌患者血浆游离DNA高通量测序的分子分型研究[J]. 中华肝脏病杂志, 2017, 25(8):626-629. DOI: 10.3760/cma.j.issn.1007-3418.2017.08.014.
[39]	Xiong Y, Xie CR, Zhang S, et al. Detection of a novel panel of somatic mutations in plasma cell-free DNA and its diagnostic value in hepatocellular carcinoma[J]. Cancer Manag Res, 2019, 11:5745-5756. DOI: 10.2147/CMAR.S197455. doi: 10.2147/CMAR.S197455 pmid: 31303788
[40]	Liu R, Shen Y, Nan K, et al. Association between expression of cancer stem cell markers and poor differentiation of hepatocellular carcinoma: a meta-analysis (PRISMA)[J]. Medicine (Baltimore), 2015, 94(31): e1306. DOI: 10.1097/MD.0000000000001306.
[41]	禹琛, 毛雨鸽, 程倩, 等. 肿瘤干细胞标志物EpCAM在肝癌肝移植患者中的表达及其与肿瘤复发转移的关系[J]. 中华普通外科杂志, 2018, 33(1):61-64. DOI: 10.3760/cma.j.issn.1007-631X.2018.01.018.
[42]	Zhu P, Wang Y, Huang G, et al. lnc-β-Catm elicits EZH2-depen-dent β-catenin stabilization and sustains liver CSC self-renewal[J]. Nat Struct Mol Biol, 2016, 23(7):631-639. DOI: 10.1038/nsmb.3235. doi: 10.1038/nsmb.3235
[43]	Wang H, Lu Z, Zhao X. Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer[J]. J Hematol Oncol, 2019, 12(1):133. DOI: 10.1186/s13045-019-0806-6. doi: 10.1186/s13045-019-0806-6
[44]	张云, 庹敏, 刘胜武. 血清外泌体来源的miRNA-122对肝癌诊断的研究[J]. 检验医学与临床, 2017, 14(9):1260-1261,1265. DOI: 10.3969/j.issn.1672-9455.2017.09.021.
[45]	Tian XP, Wang CY, Jin XH, et al. Acidic microenvironment up-regulates exosomal miR-21 and miR-10b in early-stage hepatocellular carcinoma to promote cancer cell proliferation and metastasis[J]. Theranostics, 2019, 9(7):1965-1979. DOI: 10.7150/thno.30958. doi: 10.7150/thno.30958